AnaptysBio, Inc. (NASDAQ:ANAB) Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 191.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 33,744 shares of the biotechnology company's stock after purchasing an additional 22,164 shares during the period. JPMorgan Chase & Co. owned 0.11% of AnaptysBio worth $1,130,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in ANAB. Values First Advisors Inc. acquired a new stake in shares of AnaptysBio during the third quarter worth $49,000. nVerses Capital LLC increased its position in AnaptysBio by 700.0% during the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock worth $54,000 after purchasing an additional 1,400 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in AnaptysBio by 81.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company's stock worth $195,000 after purchasing an additional 2,600 shares in the last quarter. Point72 DIFC Ltd increased its position in AnaptysBio by 680.5% during the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company's stock worth $205,000 after purchasing an additional 5,342 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in AnaptysBio during the 3rd quarter worth about $229,000.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Wedbush restated an "outperform" rating and issued a $40.00 price target (down previously from $42.00) on shares of AnaptysBio in a report on Wednesday, December 11th. Wells Fargo & Company lowered their price target on AnaptysBio from $56.00 to $40.00 and set an "overweight" rating for the company in a report on Thursday, December 12th. HC Wainwright cut AnaptysBio from a "buy" rating to a "neutral" rating and lowered their price target for the company from $52.00 to $19.00 in a report on Wednesday, December 11th. Truist Financial lowered their price target on AnaptysBio from $30.00 to $20.00 and set a "hold" rating for the company in a report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. lowered their price target on AnaptysBio from $66.00 to $36.00 and set an "overweight" rating for the company in a report on Thursday, December 19th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, AnaptysBio currently has a consensus rating of "Moderate Buy" and an average price target of $41.45.

AnaptysBio Stock Up 1.3 %

Shares of NASDAQ ANAB traded up $0.22 during midday trading on Friday, hitting $16.85. The stock had a trading volume of 481,082 shares, compared to its average volume of 602,612. The company has a market capitalization of $512.75 million, a price-to-earnings ratio of -2.77 and a beta of -0.02. AnaptysBio, Inc. has a 1-year low of $12.51 and a 1-year high of $41.31. The company has a fifty day moving average price of $17.67 and a 200 day moving average price of $27.53.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping analysts' consensus estimates of ($1.72) by $0.58. The firm had revenue of $30.02 million during the quarter, compared to analysts' expectations of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. On average, research analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current year.

Insiders Place Their Bets

In other AnaptysBio news, Director Ecor1 Capital, Llc bought 6,646 shares of AnaptysBio stock in a transaction dated Thursday, January 2nd. The stock was bought at an average cost of $12.95 per share, for a total transaction of $86,065.70. Following the purchase, the director now owns 7,880,094 shares in the company, valued at $102,047,217.30. This represents a 0.08 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 33.70% of the stock is owned by company insiders.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.